Almanack Investment Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Almanack Investment Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,411	Closed	-$2.53M	–	189
2024 Q2	$2.53M	Sell	2,411 -2,996	-55%	-$2.9M	0.43%	42
2024 Q1	$5.2M	Buy	5,407 +2,807	+108%	+$2.67M	0.89%	27
2023 Q4	$2.28M	Sell	2,600 -3,800	-59%	-$3.13M	0.42%	38
2023 Q3	$5.27M	Sell	6,400 -800	-11%	-$629K	1.02%	18
2023 Q2	$5.17M	Buy	7,200 +2,200	+44%	+$1.7M	0.91%	19
2023 Q1	$4.11M	Sell	5,000 -6,300	-56%	-$4.75M	0.81%	21
2022 Q4	$8.15M	Buy	+11,300	New	+$8.34M	1.74%	11

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Almanack Investment Partners's REGN Position: Q3 2024 in Review

Almanack Investment Partners sold out of Regeneron Pharmaceuticals (REGN) in Q3 2024, closing a stake of 2,411 shares — an estimated $2.53M sold.

Almanack Investment Partners first reported a position in REGN in Q4 2022 and held it in 7 quarters. The position peaked at $8.15M in Q4 2022. 1,388 funds tracked by Wall St. Rank hold REGN as of Q3 2024.

Almanack Investment Partners reported no remaining Regeneron Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Almanack Investment Partners sold 2,411 Regeneron Pharmaceuticals shares in Q3 2024, an estimated $2.53M.
Almanack Investment Partners first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 7 quarters.
Almanack Investment Partners's Regeneron Pharmaceuticals position peaked at $8.15M in Q4 2022.
1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2024.

Based on Almanack Investment Partners's 13F filing for Q3 2024, filed 31 Oct 2024.